Ratings changes by an analyst with Bank of America-Merrill Lynch elevated one medical device company’s stock today in pre-marker trading but pushed two others down.
Appearing this morning on Bloomberg television, BAML’s Bob Hopkins said Wall Street isn’t foucsed enough on the July 31 investor day at Cardiovascular Systems (NSDQ:CSII), according to Seeking Alpha. The St. Paul, Minn.-based company plans to emphasize new product releases in the near term and could be in store for sustained double-digit earnings growth, Hopkins said.
The analyst upgraded his rating on CSII shares from “underperform” to “buy” and boosted his price target from $30 to $40, representing a 33% premium on yesterday’s $30.78 closing price. The upgrade sent the stock up 1.1% to $31.12 today before the market’s opening.
That sent NUVA shares down -2.2% to $51.60 apiece pre-market and pared -2.7% from GMED shares, which were at $51.85 before the open.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.